YTSN Fundamental Analysis - KUROS BIOSCIENCES AG-REG

Fundamental Rating

Overall YTSN gets a fundamental rating of 4 out of 10. We evaluated YTSN against 73 industry peers in the Biotechnology industry. While YTSN has a great health rating, there are worries on its profitability. YTSN is valued quite expensive, but it does show an excellent growth.

Quickly go to:

1. Profitability

1.1 Basic Checks

YTSN had negative earnings in the past year.

In the past year YTSN had a positive cash flow from operations.

In the past 5 years YTSN always reported negative net income.

YTSN had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -5.07%, YTSN is in the better half of the industry, outperforming 63.51% of the companies in the same industry.

The Return On Equity of YTSN (-7.30%) is better than 70.27% of its industry peers.

		Industry Rank	Sector Rank
ROA	-5.07%
ROE	-7.3%
ROIC	N/A

ROA(3y)-13.96%

ROA(5y)-12.47%

ROE(3y)-17.57%

ROE(5y)-15.22%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

YTSN has a better Gross Margin (82.10%) than 74.32% of its industry peers.

In the last couple of years the Gross Margin of YTSN has grown nicely.

YTSN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	82.1%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.84%

GM growth 5Y1.82%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

YTSN does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, YTSN has more shares outstanding

The number of shares outstanding for YTSN has been increased compared to 5 years ago.

YTSN has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 25.46 indicates that YTSN is not in any danger for bankruptcy at the moment.

YTSN's Altman-Z score of 25.46 is amongst the best of the industry. YTSN outperforms 93.24% of its industry peers.

YTSN has a debt to FCF ratio of 2.44. This is a good value and a sign of high solvency as YTSN would need 2.44 years to pay back of all of its debts.

YTSN has a better Debt to FCF ratio (2.44) than 87.84% of its industry peers.

YTSN has a Debt/Equity ratio of 0.08. This is a healthy value indicating a solid balance between debt and equity.

Looking at the Debt to Equity ratio, with a value of 0.08, YTSN is in the better half of the industry, outperforming 67.57% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	2.44
Altman-Z	25.46

ROIC/WACCN/A

WACC4.99%

2.3 Liquidity

A Current Ratio of 2.14 indicates that YTSN has no problem at all paying its short term obligations.

YTSN has a Current ratio of 2.14. This is comparable to the rest of the industry: YTSN outperforms 50.00% of its industry peers.

YTSN has a Quick Ratio of 1.69. This is a normal value and indicates that YTSN is financially healthy and should not expect problems in meeting its short term obligations.

With a Quick ratio value of 1.69, YTSN perfoms like the industry average, outperforming 47.30% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	2.14
Quick Ratio	1.69

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

YTSN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 69.49%, which is quite impressive.

Looking at the last year, YTSN shows a very strong growth in Revenue. The Revenue has grown by 142.50%.

YTSN shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 105.10% yearly.

EPS 1Y (TTM)69.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%57.07%

Revenue 1Y (TTM)142.5%

Revenue growth 3Y88.78%

Revenue growth 5Y105.1%

Sales Q2Q%111.18%

3.2 Future

YTSN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 83.25% yearly.

YTSN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.92% yearly.

EPS Next Y163.21%

EPS Next 2Y101.05%

EPS Next 3Y80.1%

EPS Next 5Y83.25%

Revenue Next Year73.35%

Revenue Next 2Y48.14%

Revenue Next 3Y39.6%

Revenue Next 5Y38.92%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for YTSN. In the last year negative earnings were reported.

With a Price/Forward Earnings ratio of 485.69, YTSN can be considered very expensive at the moment.

75.68% of the companies in the same industry are more expensive than YTSN, based on the Price/Forward Earnings ratio.

When comparing the Price/Forward Earnings ratio of YTSN to the average of the S&P500 Index (22.73), we can say YTSN is valued expensively.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	485.69

4.2 Price Multiples

77.03% of the companies in the same industry are more expensive than YTSN, based on the Price/Free Cash Flow ratio.

		Industry Rank	Sector Rank
P/FCF	498.35
EV/EBITDA	N/A

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates YTSN does not grow enough to justify the current Price/Earnings ratio.

YTSN's earnings are expected to grow with 80.10% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y101.05%

EPS Next 3Y80.1%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for YTSN!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

KUROS BIOSCIENCES AG-REG

FRA:YTSN (9/5/2025, 7:00:00 PM)

27.48

+1.08 (+4.09%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-14 2025-08-14

Earnings (Next)10-16 2025-10-16

Inst Owners14.84%

Inst Owner ChangeN/A

Ins Owners1.9%

Ins Owner ChangeN/A

Market Cap1.06B

Analysts85

Price Target35.93 (30.75%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)-8.92%

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	485.69
P/S	13.38
P/FCF	498.35
P/OCF	321.87
P/B	17.2
P/tB	41.55
EV/EBITDA	N/A

EPS(TTM)-0.11

EYN/A

EPS(NY)0.06

Fwd EY0.21%

FCF(TTM)0.06

FCFY0.2%

OCF(TTM)0.09

OCFY0.31%

SpS2.05

BVpS1.6

TBVpS0.66

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-5.07%
ROE	-7.3%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	82.1%
FCFM	2.68%

ROA(3y)-13.96%

ROA(5y)-12.47%

ROE(3y)-17.57%

ROE(5y)-15.22%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y6.84%

GM growth 5Y1.82%

F-Score6

Asset Turnover0.89

Health

		Industry Rank	Sector Rank
Debt/Equity	0.08
Debt/FCF	2.44
Debt/EBITDA	N/A
Cap/Depr	42.18%
Cap/Sales	1.47%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	2.14
Quick Ratio	1.69
Altman-Z	25.46

F-Score6

WACC4.99%

ROIC/WACCN/A

Cap/Depr(3y)22.71%

Cap/Depr(5y)17.87%

Cap/Sales(3y)1.56%

Cap/Sales(5y)2.56%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)69.49%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%57.07%

EPS Next Y163.21%

EPS Next 2Y101.05%

EPS Next 3Y80.1%

EPS Next 5Y83.25%

Revenue 1Y (TTM)142.5%

Revenue growth 3Y88.78%

Revenue growth 5Y105.1%

Sales Q2Q%111.18%

Revenue Next Year73.35%

Revenue Next 2Y48.14%

Revenue Next 3Y39.6%

Revenue Next 5Y38.92%

EBIT growth 1Y43.07%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5Y357.68%

FCF growth 1Y122.12%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y135.5%

OCF growth 3YN/A

OCF growth 5YN/A

KUROS BIOSCIENCES AG-REG (YTSN.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens